CSPC Pharmaceutical Group Ltd
HKEX:1093
CSPC Pharmaceutical Group Ltd
Accounts Receivables
CSPC Pharmaceutical Group Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Accounts Receivables
¥6.9B
|
CAGR 3-Years
22%
|
CAGR 5-Years
20%
|
CAGR 10-Years
16%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accounts Receivables
¥3.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Accounts Receivables
¥791.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accounts Receivables
¥6.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accounts Receivables
¥10.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
40%
|
CAGR 10-Years
28%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Accounts Receivables
¥444.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
CSPC Pharmaceutical Group Ltd
Glance View
CSPC Pharmaceutical Group Ltd., a prominent player in the pharmaceutical industry, has charted a strategic path focused on innovation and a diversified portfolio. The company, with its roots in China, has emerged as a formidable force by blending traditional pharmaceutical manufacturing with a strong emphasis on research and development. CSPC's journey is characterized by a commitment to developing high-quality generic drugs, innovative therapeutics, and nutritional products. The company's core business revolves around the production and sale of a wide range of pharmaceuticals, including cardiovascular drugs, oncology treatments, and central nervous system therapies. By leveraging advanced technology and robust research initiatives, CSPC consistently delivers solutions that address both common and complex healthcare needs across the globe. With a strategic focus on both domestic and international markets, CSPC Pharmaceutical Group capitalizes on its extensive distribution network to maximize reach and impact. The company has made significant investments in its production capabilities to maintain stringent quality standards while achieving cost efficiency. Furthermore, CSPC's earnings are bolstered by its expanding pipeline of innovative drugs, developed in-house and through strategic collaborations, which aims to capture emerging therapeutic areas. Overall, CSPC's blend of traditional pharmaceutical expertise, a focus on innovation, and strategic market positioning enables it to maintain a strong operational foothold and to consistently drive revenue growth in an ever-evolving industry landscape.
See Also
What is CSPC Pharmaceutical Group Ltd's Accounts Receivables?
Accounts Receivables
6.9B
CNY
Based on the financial report for Sep 30, 2024, CSPC Pharmaceutical Group Ltd's Accounts Receivables amounts to 6.9B CNY.
What is CSPC Pharmaceutical Group Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
16%
Over the last year, the Accounts Receivables growth was 21%. The average annual Accounts Receivables growth rates for CSPC Pharmaceutical Group Ltd have been 22% over the past three years , 20% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet